Information Provided By: 
Fly News Breaks for March 23, 2018
BMRN
Mar 23, 2018 | 09:04 EDT
SunTrust analyst Edward Nash writes that his review of the latest FDA briefing document released ahead of Adcom meeting discussing the drug development for the treatment of children with achondroplasia may be a positive for Biomarin. Nash notes that the company is "established as a leader in the space" and its current trial design with top-line Phase 3 data expected in late 2019 may exceed FDA expectations. The analyst keeps his Buy rating and a $130 price target on BioMarin.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
